CN115120692A - Diglyceride composition for reducing blood fat and preparation method thereof - Google Patents
Diglyceride composition for reducing blood fat and preparation method thereof Download PDFInfo
- Publication number
- CN115120692A CN115120692A CN202210804111.2A CN202210804111A CN115120692A CN 115120692 A CN115120692 A CN 115120692A CN 202210804111 A CN202210804111 A CN 202210804111A CN 115120692 A CN115120692 A CN 115120692A
- Authority
- CN
- China
- Prior art keywords
- parts
- diglyceride
- powder
- composition
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 210000004369 blood Anatomy 0.000 title abstract description 55
- 239000008280 blood Substances 0.000 title abstract description 55
- 230000001603 reducing effect Effects 0.000 title abstract description 26
- 210000000582 semen Anatomy 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 29
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 24
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 17
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 17
- 241000545744 Hirudinea Species 0.000 claims abstract description 17
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 17
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 13
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 11
- 241001061264 Astragalus Species 0.000 claims abstract description 8
- 210000004233 talus Anatomy 0.000 claims abstract description 8
- 244000088415 Raphanus sativus Species 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 71
- 239000008187 granular material Substances 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 18
- 240000009138 Curcuma zedoaria Species 0.000 claims description 14
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 14
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 14
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 14
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 14
- 235000019509 white turmeric Nutrition 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 241000112528 Ligusticum striatum Species 0.000 claims description 10
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 235000014375 Curcuma Nutrition 0.000 claims description 9
- 244000164480 Curcuma aromatica Species 0.000 claims description 9
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 241000382455 Angelica sinensis Species 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 240000007651 Rubus glaucus Species 0.000 claims description 4
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 4
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 240000005717 Dioscorea alata Species 0.000 claims description 2
- 241001252483 Kalimeris Species 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 52
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 29
- 239000000463 material Substances 0.000 abstract description 25
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 24
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 21
- 210000002966 serum Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 235000012000 cholesterol Nutrition 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 235000019197 fats Nutrition 0.000 description 28
- 239000003921 oil Substances 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 238000001035 drying Methods 0.000 description 18
- 108010023302 HDL Cholesterol Proteins 0.000 description 17
- 238000002137 ultrasound extraction Methods 0.000 description 16
- 229920002774 Maltodextrin Polymers 0.000 description 15
- 239000005913 Maltodextrin Substances 0.000 description 15
- 229940035034 maltodextrin Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000010992 reflux Methods 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 241000220259 Raphanus Species 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000005325 percolation Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 235000012239 silicon dioxide Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000006463 Brassica alba Nutrition 0.000 description 7
- 244000140786 Brassica hirta Species 0.000 description 7
- 235000011371 Brassica hirta Nutrition 0.000 description 7
- 241000628997 Flos Species 0.000 description 7
- 241000237903 Hirudo Species 0.000 description 7
- 239000009636 Huang Qi Substances 0.000 description 7
- 241000243684 Lumbricus Species 0.000 description 7
- 235000004347 Perilla Nutrition 0.000 description 7
- 244000124853 Perilla frutescens Species 0.000 description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 7
- 241000220261 Sinapis Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004376 Sucralose Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000011812 mixed powder Substances 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 5
- 235000019408 sucralose Nutrition 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 241000212322 Levisticum officinale Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000001188 Peltandra virginica Nutrition 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 241000913745 Spatholobus Species 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000001645 levisticum officinale Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229940067631 phospholipid Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000001508 potassium citrate Substances 0.000 description 3
- 229960002635 potassium citrate Drugs 0.000 description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
- 235000011082 potassium citrates Nutrition 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- 229940080237 sodium caseinate Drugs 0.000 description 3
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229960001790 sodium citrate Drugs 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a diglyceride composition for reducing blood fat and a preparation method thereof. The composition comprises the following components: diglyceride, radix salviae miltiorrhizae, angelica, caulis spatholobi, peach kernel, safflower, astragalus, cassia twig, earthworm, leech, rhizoma zedoariae, rhizoma ligustici wallichii, perillaseed, radish seed, semen brassicae, rhizoma acori graminei, poria cocos and arillus longan; the composition can effectively reduce blood fat and contents of Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in serum, and the diglyceride is added into a traditional Chinese medicine formula to act together, so that the effect of the composition is far better than that of the single diglyceride or the single traditional Chinese medicine formula. The invention also provides a preparation method of the composition, the traditional Chinese medicine is prepared into dry extract by the processes of extraction, purification and the like, and then the dry extract, the diglyceride and the auxiliary materials are added or not added to prepare the product, the process is simple and convenient, and the industrial production is convenient.
Description
Technical Field
The invention relates to the technical field of food, and in particular relates to a diglyceride traditional Chinese medicine composition for reducing blood fat and a preparation method thereof.
Background
Modern people have higher living level, more and more abundant food, rich and sweet food, busy work and lack of sports, which cause multiple obesity diseases and high blood fat, or part of people are not particularly obese, but the blood fat level is also very high. Therefore, in recent years, obesity, hyperlipidemia and other related cardiovascular and cerebrovascular diseases are increasing, and the health and the quality of life of people are seriously affected.
High blood fat, generally has the following indexes in biochemical detection: serum Total Cholesterol (TC), Triglyceride (TG), low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C). Wherein the lower the serum Total Cholesterol (TC), Triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), the healthier the body is, and the higher the high density lipoprotein cholesterol (HDL-C) is, the healthier the body is.
According to the traditional Chinese medicine, the traditional Chinese medicine belongs to the category of fat people, the constitution of the traditional Chinese medicine is excessive and stagnant or the phlegm and blood stasis are combined, and the patients have the symptoms of chest distress, short breath, deep and weak pulse and the like. The diseases such as apoplexy, hemiplegia and the like are easy to cause, are all fierce, are easy to threaten life, are a long-term process even if better treatment is obtained, and have a plurality of sequelae, thereby seriously affecting the life quality.
Therefore, in order to meet the requirement of people on blood lipid health, it is very necessary to develop a healthy product capable of safely and effectively reducing blood lipid.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition capable of safely and effectively reducing blood fat, a diglyceride traditional Chinese medicine composition and a preparation method thereof aiming at the requirement of people on blood fat health.
The technical scheme adopted by the invention is as follows:
in a first aspect of the present invention, a composition is provided, which comprises the following Chinese medicinal components: radix salviae miltiorrhizae, angelica, caulis spatholobi, peach kernel, safflower, astragalus, cassia twig, earthworm, leech, rhizoma zedoariae, rhizoma ligustici wallichii, perillaseed, radish seed, semen brassicae, rhizoma acori graminei, poria cocos and arillus longan.
Wherein, the angelica, the salvia miltiorrhiza and the caulis spatholobi have the functions of promoting blood circulation and activating blood, nourishing heart blood and tonifying liver blood; the leech and the earthworm can activate blood and remove stasis, dredge channels and collaterals and break stasis; safflower and peach seed have the functions of promoting blood circulation by removing blood stasis, and zedoary has the functions of removing blood stasis and promoting blood circulation; the ligusticum wallichii is a medicine for promoting blood circulation and qi circulation, the astragalus mongholicus can tonify qi and promote diuresis, and the cassia twig can warm and dredge channels and collaterals, and can promote qi and blood circulation and warm and circulate blood to reach extremities; the angelica enriches the blood, the arillus longan invigorates the heart and spleen, nourishes the blood, the poria cocos invigorates the spleen and calms the heart, and the spleen and the blood are jointly supplemented and generated, so that the qi and the blood have the source of generation; tuckahoe, rhizoma acori graminei and astragalus root have the effects of eliminating dampness, and the astragalus root has the effects of promoting diuresis and combining the effects of dispelling the effects of the medicines; the perilla fruit, the radish seed, the white mustard seed and the grassleaf sweelflag rhizome are three-seed nourishing soup and the grassleaf sweelflag rhizome has the effects of warming lung and reducing phlegm, inducing resuscitation and eliminating phlegm, resolving dampness and stimulating appetite, descending qi and promoting digestion, and also has the effects of reducing phlegm and strengthening spleen and stomach and solves the problem of generating phlegm. The medicines are combined to be used for strengthening the spleen, dispelling dampness, reducing phlegm, enriching blood and generating blood, promoting blood circulation and nourishing blood, warming yang and tonifying qi, removing blood stasis and dredging collaterals, and breaking blood and removing blood stasis, so that the hyperlipidemia problem caused by mutual combination of phlegm and blood stasis is effectively solved.
Specifically, the composition according to the first aspect of the invention comprises the following traditional Chinese medicine components in parts by weight: 10-30 parts of salvia miltiorrhiza, 5-15 parts of angelica sinensis, 10-25 parts of caulis spatholobi, 5-15 parts of peach kernel, 5-15 parts of safflower, 20-40 parts of astragalus membranaceus, 10-25 parts of cassia twig, 5-15 parts of earthworm, 5-15 parts of leech, 10-25 parts of curcuma zedoary, 10-25 parts of ligusticum wallichii, 5-15 parts of perillaseed, 5-15 parts of airy yam rhizome, 5-15 parts of airy kalimeris herb, 5-15 parts of semen brassicae, 5-15 parts of rhizoma acori graminei, 10-25 parts of poria cocos and 10-25 parts of arillus longan.
Further, according to the composition of the first aspect of the present invention, the composition further comprises diglyceride.
Diglycerides, which are natural components present in edible oils, are present in small amounts, generally less than 2%, and the majority of edible oils are triglycerides, generally greater than 98%. Experimental studies show that diglyceride can stimulate fat oxidation and improve metabolic rate (RMR), and by eating diglyceride, the body weight can be controlled more effectively, the body fat content can be reduced, the levels of triglyceride in the serum and the liver of a rat can be reduced remarkably, blood fat and fasting blood glucose can be reduced, and the body fat accumulation caused by high-fat diet can be inhibited.
Preferably, the composition according to the first aspect of the present invention comprises the following components in parts by weight: 50-100 parts of diglyceride, 10-30 parts of salvia miltiorrhiza, 5-15 parts of angelica sinensis, 10-25 parts of caulis spatholobi, 5-15 parts of peach kernel, 5-15 parts of safflower, 20-40 parts of astragalus membranaceus, 10-25 parts of cassia twig, 5-15 parts of earthworm, 5-15 parts of leech, 10-25 parts of curcuma zedoary, 10-25 parts of ligusticum wallichii, 5-15 parts of perillaseed, 5-15 parts of airy raspberry, 5-15 parts of semen brassicae, 5-15 parts of rhizoma acori graminei, 10-25 parts of poria cocos and 10-25 parts of arillus longan.
More preferably, the composition according to the first aspect of the present invention comprises the following ingredients in parts by weight: 55-95 parts of diglyceride, 15-25 parts of salvia miltiorrhiza, 8-12 parts of angelica sinensis, 12-20 parts of caulis spatholobi, 8-12 parts of peach kernel, 8-12 parts of safflower, 25-35 parts of astragalus membranaceus, 12-20 parts of cassia twig, 8-12 parts of earthworm, 8-12 parts of leech, 12-20 parts of curcuma zedoary, 12-20 parts of ligusticum wallichii, 8-12 parts of perillaseed, 8-12 parts of airy raspberry, 8-12 parts of semen raphani, 8-12 parts of semen brassicae, 8-12 parts of rhizoma acori graminei, 12-20 parts of poria cocos and 12-20 parts of arillus longan.
In a second aspect of the invention, there is provided a product, the main component of which is prepared from the composition according to the first aspect of the invention.
In particular, the product according to the first aspect of the present invention is a health product, a pharmaceutical product or a daily chemical product.
Preferably, according to the product of the first aspect of the present invention, the Chinese medicinal ingredients are prepared into extract, granule or powder.
More preferably, the Chinese medicinal components are prepared into extract, granules or powder by a water decoction extraction method, an ethanol reflux extraction method, a percolation extraction method, an ultrasonic extraction method or an ultrahigh pressure extraction method.
Wherein, the reflux extraction is carried out by adding water and ethanol with different concentrations, and is a heat extraction method, and in the ethanol reflux extraction method, the concentration of the ethanol is 10-70% by volume fraction; the percolation extraction method, the ultrasonic extraction method and the ultrahigh pressure extraction method are cold extraction methods, and are not heated, so that the effective ingredients in the traditional Chinese medicinal materials cannot be damaged; in the ultrasonic extraction method, ultrasonic waves have strong cavitation, cell walls can be broken, effective components can be dissolved out quickly and completely, the extraction efficiency is high, and the effective components are extracted completely.
The ultrahigh pressure extraction method is similar to the ultrasonic extraction method, the ultrahigh pressure is firstly added, then the pressure is released in a short time, so that cell walls are broken, the effective components can be quickly and completely dissolved out, the extraction efficiency is high, and the effective components are completely extracted. The percolation extraction method has low efficiency, long time consumption and incomplete dissolution of effective components.
More preferably, the preparation is carried out by ultrasonic extraction and ultrahigh pressure extraction, most preferably ultrasonic extraction, so that the cost can be controlled, and the subsequent large-scale production of products is facilitated.
Preferably, according to the product of the first aspect of the invention, the diglyceride is a solid granule or a powder.
Preferably, the product according to the first aspect of the present invention further comprises pharmaceutically acceptable excipients.
In a third aspect of the invention, there is provided a process for the preparation of a product according to the second aspect of the invention,
extracting, filtering, purifying and concentrating the traditional Chinese medicine components into extract, granules or powder;
adding diglyceride solid granules or powder;
mixing the two solutions uniformly.
More preferably, the Chinese medicinal components are prepared into extract, granules or powder by a water decoction extraction method, an ethanol reflux extraction method, a percolation extraction method, an ultrasonic extraction method or an ultrahigh pressure extraction method.
Wherein, the reflux extraction is carried out by adding water and ethanol with different concentrations, and is a thermal extraction method, and in the ethanol reflux extraction method, the concentration of the ethanol is 10-70% by volume fraction; the percolation extraction method, the ultrasonic extraction method and the ultrahigh pressure extraction method are cold extraction methods, and are not heated, so that the effective ingredients in the traditional Chinese medicinal materials cannot be damaged; the ultrasonic extraction method is characterized in that the ultrasonic strong cavitation action breaks cell walls, so that effective components can be quickly and completely dissolved out, the extraction efficiency is high, and the effective components are completely extracted.
The ultrahigh pressure extraction method is similar to the ultrasonic extraction method, the ultrahigh pressure is firstly added, then the pressure is released in a short time, so that cell walls are broken, the effective components can be quickly and completely dissolved out, the extraction efficiency is high, and the effective components are completely extracted. The percolation extraction method has low efficiency, long time consumption and incomplete dissolution of effective components.
More preferably, the preparation is carried out by ultrasonic extraction and ultrahigh pressure extraction, most preferably ultrasonic extraction, so that the cost can be controlled, and the subsequent large-scale production of products is facilitated.
Preferably, according to the preparation method of the third aspect of the present invention, the diglyceride solid granules or powders are prepared by adding an emulsifier, a pH adjuster, and an antioxidant to diglyceride.
More specifically, the method for preparing the diglyceride into solid granules or powder comprises the following steps: mixing diglyceride with one or more of wall material, sodium caseinate, mono-diglyceride fatty acid ester, sodium ascorbate, dipotassium hydrogen phosphate, potassium citrate, sodium citrate, vitamin E, phospholipid, etc., emulsifying, and drying to obtain the diglyceride solid granule or powder.
In some embodiments, the method of preparing the diglyceride into solid granules or powder comprises: mixing diglyceride oil with one or more of resistant dextrin, isomaltooligosaccharide, polydextrose, maltodextrin, sodium caseinate, mono-diglycerol fatty acid ester, sodium ascorbate, dipotassium hydrogen phosphate, potassium citrate, sodium citrate, vitamin E, and phospholipid, emulsifying, spray drying, and optionally adding silicon dioxide to obtain solid granule or powder
The diglyceride solid granules or powder can also adopt conventional commercially available diglyceride powder or granules.
More preferably, the drying method is a vacuum drying method, a microwave drying method or a spray drying method.
More preferably, the granulation method is a wet granulation method, a one-step granulation method, or a dry granulation method.
Wherein the one-step granulation method is to directly dry and granulate the extract, such as placing in a boiling drying granulator for one-step granulation, and the method can dry the extract in a short time, has little thermal damage to effective components, and is a more preferable granulation method
Furthermore, silicon dioxide can be added or not added in or after the granulating and drying processes so as to reduce the hygroscopicity of the prepared material and facilitate the storage of the material.
Preferably, according to the preparation method of the third aspect of the present invention, the soft extract is dried and pulverized to obtain dry extract powder, and the dry extract powder is uniformly mixed with an appropriate amount of excipients and diglyceride oil powder to prepare solid powder or granules; or, granulating the soft extract with appropriate amount of adjuvants and diglyceride oil powder to obtain granule.
The invention has the beneficial effects that:
the invention provides a composition for safely and effectively reducing blood fat, which utilizes reasonable combination of diglyceride oil powder and a plurality of traditional Chinese medicinal materials, can effectively solve the problem of hyperlipidemia, can effectively reduce blood fat, and effectively reduce the contents of total serum cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), and the traditional Chinese medicinal materials are common traditional Chinese medicinal materials, have no toxicity, are high in safety, are healthy products which can be taken for a long time, and are added with a traditional Chinese medicine formula to play a role together with diglyceride, and the effect of the composition is far better than that of single diglyceride or a single traditional Chinese medicine formula.
The invention also provides a preparation method of the composition, the traditional Chinese medicine is prepared into dry extract by the processes of extraction, purification and the like, and then the dry extract, the diglyceride and the auxiliary materials are added or not added to prepare the product, the process is simple and convenient, and the industrial production is convenient.
Detailed Description
The present invention will be described in further detail with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 55 parts of diglyceride oil powder, 15 parts of salvia miltiorrhiza, 15 parts of angelica, 10 parts of caulis spatholobi, 12 parts of peach kernel, 5 parts of safflower, 35 parts of astragalus, 22 parts of cassia twig, 8 parts of earthworm, 8 parts of leech, 22 parts of curcuma zedoary, 12 parts of ligusticum wallichii, 10 parts of perillaseed, 12 parts of radish seed, 15 parts of semen brassicae, 5 parts of rhizoma acori graminei, 20 parts of poria cocos and 18 parts of arillus longan.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, and mixing to obtain mixture;
(2) placing the mixed medicinal materials in the step (1) in an extraction tank, adding 8 times of water, soaking for 2 hours, boiling, heating and refluxing for extraction for 1.5 hours, filtering, standing for use, adding 7 times of water into filter residues, heating and refluxing for extraction for 1.5 hours, filtering, combining the filtrates for 2 times, and concentrating under reduced pressure to obtain thick paste;
(3) putting the thick paste obtained in the step (2) into a vacuum drying oven, and drying under the conditions: drying at 75 deg.C and vacuum degree below-0.085 Mpa, taking out, and pulverizing to obtain dry extract powder;
(4) and (3) adding 25 parts of maltodextrin, 0.1 part of silicon dioxide, 0.05 part of sucralose and the diglyceride oil powder according to the formula amount into the dry paste powder obtained in the step (3), and uniformly mixing in a multi-direction motion mixer to obtain powder.
(5) Or further performing one step to add the mixed powder obtained in the step (4) into a dry granulating machine, pressing, and granulating to obtain granules. The diglyceride oil powder can be commercially available diglyceride powder or granules, and can also be prepared by the following preparation method: mixing diglyceride oil with one or more of resistant dextrin, isomaltose hypgather, polydextrose, maltodextrin and other wall materials, sodium caseinate, mono-diglycerol fatty acid ester, sodium ascorbate, dipotassium hydrogen phosphate, potassium citrate, sodium citrate, vitamin E, phospholipid, etc., emulsifying, spray drying, and optionally adding silicon dioxide to obtain solid granule or powder.
Example 2
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 60 parts of diglyceride oil powder, 30 parts of salvia miltiorrhiza, 5 parts of angelica, 12 parts of suberect spatholobus stem, 15 parts of peach seed, 12 parts of safflower, 40 parts of astragalus, 10 parts of cassia twig, 10 parts of earthworm, 12 parts of leech, 20 parts of zedoary, 18 parts of szechuan lovage rhizome, 8 parts of perilla fruit, 10 parts of radish seed, 12 parts of white mustard seed, 8 parts of grassleaf sweelflag rhizome, 22 parts of tuckahoe and 12 parts of longan pulp.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, and mixing to obtain mixture;
(2) placing the mixed medicinal materials in the step (1) in an extraction tank, adding 8 times of 70% ethanol, soaking for 2 hours, heating and refluxing for extraction for 1.5 hours, filtering, standing for use, adding 7 times of 30% ethanol into filter residues, heating and refluxing for extraction for 1.5 hours, filtering, combining the filtrates for 2 times, and concentrating under reduced pressure to obtain thick paste;
(3) putting the thick paste obtained in the step (2) into a microwave vacuum drying oven, and drying under the following conditions: the temperature of the dried material is kept at 50 ℃, the vacuum degree is gradually increased to-0.085 Mpa, and the condition of the material is observed from an observation window without overflowing the tray. After drying, taking out and crushing to obtain dry paste powder;
(4) and (3) adding 25 parts of maltodextrin, 0.1 part of silicon dioxide, 0.05 part of sucralose and the diglyceride oil powder according to the formula amount into the dry paste powder obtained in the step (3), and uniformly mixing in a multi-direction motion mixer to obtain powder.
(5) Or further adding the mixed powder obtained in the step (4) into a dry granulating machine, pressing, and grading to obtain granules, thus obtaining the granules.
Example 3
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 70 parts of diglyceride oil powder, 25 parts of salvia miltiorrhiza, 8 parts of angelica, 15 parts of suberect spatholobus stem, 12 parts of peach seed, 8 parts of safflower, 35 parts of astragalus, 12 parts of cassia twig, 15 parts of earthworm, 12 parts of leech, 18 parts of zedoary, 20 parts of szechuan lovage rhizome, 10 parts of perilla fruit, 8 parts of radish seed, 8 parts of white mustard seed, 10 parts of grassleaf sweelflag rhizome, 18 parts of tuckahoe and 20 parts of longan pulp.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, and mixing to obtain mixture;
(2) placing the mixed medicinal materials in the step (1) into an extraction tank, adding 8 times of 60% ethanol, soaking for 2 hours, heating and refluxing for extraction for 1.5 hours, filtering, standing by filtrate, adding 7 times of 60% ethanol into filter residue, heating and refluxing for extraction for 1.5 hours, filtering, combining 2 times of filtrates, recovering ethanol and concentrating under reduced pressure to obtain thick paste;
(3) putting the thick paste obtained in the step (2) into a vacuum drying oven, and drying under the conditions: drying at 75 deg.C under-0.085 Mpa, taking out, and pulverizing to obtain dry extract powder;
(4) and (3) adding 25 parts of maltodextrin, 0.1 part of silicon dioxide, 0.05 part of sucralose and the diglyceride oil powder according to the formula amount into the dry paste powder obtained in the step (3), and uniformly mixing in a multi-direction motion mixer to obtain a powder preparation.
(5) Or further granulating the mixed powder obtained in the step (4) by a wet method, adding into a boiling drying granulator, and drying by hot air to obtain granules.
Example 4
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 90 parts of diglyceride oil powder, 10 parts of salvia miltiorrhiza, 12 parts of angelica, 18 parts of suberect spatholobus stem, 8 parts of peach seed, 12 parts of safflower, 20 parts of astragalus, 25 parts of cassia twig, 12 parts of earthworm, 5 parts of leech, 25 parts of zedoary, 10 parts of szechuan lovage rhizome, 12 parts of perilla fruit, 15 parts of radish seed, 5 parts of white mustard seed, 15 parts of grassleaf sweelflag rhizome, 10 parts of tuckahoe and 25 parts of longan pulp.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, mixing, and pulverizing to obtain crude powder;
(2) and (2) placing the crude powder of the medicinal materials in the step (1) in an ultrahigh pressure extractor, and adding 50% ethanol in an amount which is 6 times that of the crude powder for extraction. Extraction conditions are as follows: soaking for 30 minutes under the pressure of 400MPa, maintaining the pressure for 3 minutes, and circulating for 10 times at normal temperature. After extraction, centrifuging, adding 10% ethanol 6 times the amount of the centrifugate for extraction, extracting the residue once under the same conditions as above, centrifuging, mixing the centrifugates for 2 times, recovering ethanol, and concentrating under reduced pressure to obtain soft extract;
(3) slowly adding 5 parts of maltodextrin into the thick paste obtained in the step (2), uniformly stirring, and carrying out spray drying to obtain spray-dried powder. And (3) drying: air inlet temperature 175-: 75-80 ℃, atomization pressure: 0.24Mpa, keeping the temperature of the thick paste at 70-75 ℃, and obtaining the thick paste with the relative density of 1.10-1.12 (5 parts of maltodextrin is added and 50 ℃) in the step (2).
(4) And (3) adding 20 parts of maltodextrin, 0.1 part of silicon dioxide, 0.05 part of sucralose and the diglyceride oil powder according to the formula amount into the dry paste powder obtained in the step (3), and uniformly mixing in a multi-direction motion mixer to obtain a powder preparation.
(5) Or further adding the mixed powder obtained in the step (4) into a dry granulating machine, pressing, and grading to obtain granules, thus obtaining the granules.
Example 5
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 80 parts of diglyceride oil powder, 20 parts of salvia miltiorrhiza, 10 parts of angelica, 20 parts of caulis spatholobi, 5 parts of peach kernel, 15 parts of safflower, 25 parts of astragalus membranaceus, 18 parts of cassia twig, 12 parts of earthworm, 15 parts of leech, 10 parts of curcuma zedoary, 25 parts of ligusticum wallichii, 12 parts of perillaseed, 5 parts of radish seed, 12 parts of semen brassicae, 8 parts of rhizoma acori graminei, 25 parts of poria cocos and 10 parts of arillus longan.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, mixing, and pulverizing to obtain coarse powder;
(2) placing the crude powder of the medicinal materials in the step (1) into an ultrasonic extractor, adding 70% ethanol in an amount which is 6 times that of the crude powder, and carrying out ultrasonic extraction for 40 minutes under the extraction conditions: temperature 35 ℃, ultrasonic power: 1200 watts per single head, 2 seconds on ultrasound stop for 1 second. Performing ultrasonic treatment, centrifuging, adding 5 times of 30% ethanol into the residue, performing ultrasonic extraction for 40 min, combining the centrifugates for 2 times, recovering ethanol, and concentrating under reduced pressure to obtain soft extract;
(3) placing 0.05 part of silicon dioxide, 25 parts of maltodextrin and diglyceride oil powder according to the formula amount in a boiling drying granulator, spraying the thick paste obtained in the step (2), and carrying out one-step granulation under the conditions: inlet air temperature 102 ℃, material temperature 60 ℃, outlet air temperature: 45-50 ℃, atomization pressure: 0.22Mpa, the relative density of the thick paste prepared in the step (2) is 1.08-1.1(50 ℃). After spraying, taking out of the pot, and finishing granules to obtain the granules.
Example 6
A diglyceride composition with a blood fat reducing effect comprises the following active ingredients: 80 parts of diglyceride oil powder, 25 parts of salvia miltiorrhiza, 8 parts of angelica, 22 parts of suberect spatholobus stem, 8 parts of peach kernel, 10 parts of safflower, 30 parts of astragalus, 20 parts of cassia twig, 5 parts of earthworm, 10 parts of leech, 12 parts of zedoary, 22 parts of szechuan lovage rhizome, 15 parts of perilla fruit, 10 parts of radish seed, 10 parts of white mustard seed, 12 parts of grassleaf sweelflag rhizome, 12 parts of poria cocos and 22 parts of longan aril.
The preparation method of the composition with the efficacy of reducing blood fat comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, mixing, and pulverizing to obtain crude powder;
(2) adding 2 times of 50% ethanol into the crude powder of the medicinal material obtained in the step (1), soaking for one night (more than 12 hours), transferring to a percolation extraction tank, adding 10 times of 50% ethanol, and performing percolation extraction at a percolation speed: 20 ml/(min x kg medicinal materials), after the percolation is finished, recovering ethanol from the extracting solution and concentrating under reduced pressure to obtain thick paste;
(3) placing 0.05 part of silicon dioxide, 25 parts of maltodextrin and diglyceride oil powder according to the formula amount in a boiling drying granulator, spraying the thick paste obtained in the step (2), and carrying out one-step granulation under the conditions: inlet air temperature 102 ℃, material temperature 60 ℃, outlet air temperature: 45-50 ℃, atomization pressure: 0.22Mpa, and the relative density of the thick paste prepared in the step (2) is 1.08-1.1(50 ℃). After spraying, taking out of the pot, and finishing granules to obtain the granules.
Example 7
A diglyceride composition with the efficacy of reducing blood fat comprises the following active ingredients: 90 parts of diglyceride oil powder, 20 parts of salvia miltiorrhiza, 10 parts of angelica sinensis, 15 parts of caulis spatholobi, 10 parts of peach kernel, 10 parts of safflower, 30 parts of astragalus membranaceus, 15 parts of cassia twig, 10 parts of earthworm, 10 parts of leech, 15 parts of curcuma zedoary, 15 parts of ligusticum wallichii, 10 parts of perillaseed, 10 parts of radish seed, 10 parts of semen brassicae, 10 parts of rhizoma acori graminei, 15 parts of poria cocos and 15 parts of arillus longan.
The preparation method of the diglyceride composition with the blood fat reducing effect comprises the following steps:
(1) weighing Saviae Miltiorrhizae radix, radix Angelicae sinensis, caulis Spatholobi, semen Persicae, Carthami flos, radix astragali, ramulus Cinnamomi, Lumbricus, Hirudo, Curcumae rhizoma, rhizoma Ligustici Chuanxiong, fructus Perillae, Raphani semen, semen Sinapis Albae, rhizoma Acori Graminei, Poria, and arillus longan according to formula, mixing, and pulverizing to obtain crude powder;
(2) placing the crude powder of the medicinal materials in the step (1) into an ultrasonic extractor, adding 50% ethanol in an amount which is 6 times that of the crude powder, and carrying out ultrasonic extraction for 40 minutes under the extraction conditions: temperature 35 ℃, ultrasonic power: 1200 watts per single head, 2 seconds on ultrasound stop for 1 second. Completing ultrasonic treatment, centrifuging, adding 10% ethanol 5 times the amount of the centrifugate, performing ultrasonic extraction for 40 min, combining centrifugates for 2 times, recovering ethanol, and concentrating under reduced pressure to obtain soft extract;
(3) slowly adding 5 parts of maltodextrin into the thick paste obtained in the step (2), uniformly stirring, and carrying out spray drying to obtain spray-dried powder. And (3) drying: air inlet temperature 175-: 75-80 ℃, atomization pressure: 0.24Mpa, keeping the temperature of the thick paste at 70-75 ℃, and obtaining the thick paste with the relative density of 1.10-1.12 (5 parts of maltodextrin is added and 50 ℃) in the step (2).
(4) And (3) uniformly mixing the spray-dried powder prepared in the step (3) with 20 parts of maltodextrin, 0.1 part of silicon dioxide, 0.05 part of sucralose and the diglyceride oil powder according to the formula amount in a multidirectional motion mixer to obtain powder.
(5) Or further adding the mixed powder obtained in the step (4) into a dry granulating machine, pressing, and granulating to obtain granules.
Comparative example 1
Compared with the example 7, the rest materials are prepared according to the method of the example 7 except that 4 medicinal materials of perilla fruit, radish seed, white mustard seed and grassleaf sweelflag rhizome are not added in the traditional Chinese medicine part, and the sample of the comparative example 1 is obtained. The sample formulation was a powder, and the weight of the sample prepared per prescription was the same as example 7, but insufficient maltodextrin to make up.
Comparative example 2
In comparison with example 7, the procedure of example 7 was followed except that the diglyceride oil powder was not added, to obtain a sample of comparative example 2. The sample formulation was a powder, and the weight of the sample prepared per prescription was the same as example 7, but insufficient maltodextrin to make up.
Example 8
The diglyceride traditional Chinese medicine compositions of examples 1 to 7 respectively record the extraction method, the used extraction solvent and the drying method, and calculate the yield of the dry extract and record the properties of the product. The results are shown in table 1 below.
TABLE 1 EXAMPLES 1-7 Properties of Chinese medicinal-diglyceride complexes
From the records in table 1, it can be seen that, taking into account that the working examples 4 and 7 are preferred examples, the dry extract obtained by extraction is more, the dissolution is fast, the smell is natural, and the working example 7 is the best example combining the comprehensive factors of the production process and the production equipment cost, so the comparative examples 1 and 2 are prepared by the working example 7.
Effects of the embodiment
1. Construction of Mixed type hyperlipemia animal model
The principle is as follows: an animal model of lipid metabolism disorder can be formed by feeding an animal with a feed containing cholesterol, sucrose, lard, and sodium cholate, and then administering a test sample to the animal, whereby the effect of the test sample on hyperlipidemia can be detected, and the effect of the test sample on lipid absorption, lipoprotein formation, and lipid degradation or excretion can be determined.
Instruments and reagents: dissecting apparatus, spectrophotometer, automatic biochemical analyzer, cholesterol, sodium cholate, serum Total Cholesterol (TC), Triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) survey kit, the kit producer: nanjing was established as a bioengineering institute.
Animal selection and feed: healthy adult male SD rats, purchased from southern medical university animal testing center, weighed 200 ± 20g at the end of the acclimation period.
Model feed: the maintenance feed is added with 20.0 percent of cane sugar, 15.0 percent of lard, 1.2 percent of cholesterol, 0.2 percent of sodium cholate, and proper amount of casein, calcium hydrophosphate, stone powder and the like. In addition to crude fat, moisture, crude protein, crude fat, crude fiber, crude ash, calcium, phosphorus, calcium of the model feed: the phosphorus reaches the national standard of maintaining the feed.
Dose grouping and test sample administration time: experiments were carried out in examples 1 to 7, comparative examples 1 and 2, a blank control group, a positive control group (simvastatin 0.72mg/kg) and a pathology model control group (gavage with an equivalent amount of saline). Calculating the dosage: the human body is recommended to take 20g of the finished product every day, and the weight is 0.367 g/kg of the body weight according to 70 kg of the body weight, and the SD rat is perfused by 5 times (1.835 g/kg) of the recommended amount of the human body. The test sample was administered for 21 days. Note: the normal recommended dose of simvastatin for the hyperlipemia population is 10 mg/day, the human body is calculated by 70 kg body weight, the rat is calculated by 5 times the human body dose, and the rat is intragastrically administered by 0.72mg/kg every day.
The experimental steps are as follows:
an adaptation period: after the rats were purchased, the rats were fed with maintenance feed and observed for 5 days.
And (3) molding: the animals were randomly divided into 2 groups by weight, 10 rats were given maintenance feed as a blank control group, and 120 rats were given model feed as a model group. Body weight was weighed 1 time per week. After the model group was given model feed for 2 weeks, the rats in the blank control group and the model group were not fasted to take blood (tail), and serum was separated as soon as possible after blood taking to measure the TC, TG, LDL-C, HDL-C levels in the serum. The model groups are randomly divided into 11 groups according to the serum TC level (redundant discarding), and after the division, the differences of TC, TG and LDL-C, HDL-C among the model groups (total 11 groups) have no significance; compared with a blank control group, the model group (total 11 groups) has the advantages that TC, TG and LDL-C are increased and have significance in difference, and the model is successfully molded.
Test sample administration: after grouping, the test samples were orally administered daily to each of examples 1 to 7 and comparative examples 1 and 2, simvastatin was administered to the positive control group at 0.72mg/kg, the same volume of saline was simultaneously administered to the blank control group and the model control group, the maintenance feed was continuously administered to the blank control group, the model feed was continuously administered to each of the model control group, examples 1 to 7, comparative examples 1 and 2 and the positive control group, and the body weight was regularly measured, after 21 days of experiment, blood was collected without fasting from the tail, serum was rapidly separated, serum TC, TG, and LDL-C, HDL-C levels were measured, and the results are shown in table 2 below.
TABLE 2 serum TC, TG, LDL-C, HDL-C level measurement results
Note: "+" indicates significant difference from "model control group".
From the above results: compared with a model control group and a blank control group, the serum triglyceride is increased, the serum total cholesterol or the low density lipoprotein cholesterol is increased, and the difference is significant. And (3) effect analysis: (1) compared with the model control group, the serum Total Cholesterol (TC), the serum Triglyceride (TG) and the low-density lipoprotein cholesterol (HDL-C) of each implementation example group, the comparison example group and the positive control group are reduced, the difference is significant, and the serum high-density lipoprotein cholesterol (HDL-C) of each group is higher than that of the model control group, but the significance is not particularly significant, and the result shows that the samples have the effects of positively regulating cholesterol and triglyceride, have significant effects and can play a role in reducing blood fat; (2) from the test data, the data of the group 7 of the implementation example is the best and is slightly better than that of the positive control group, and the data of the group 4 of the implementation example is close to that of the group 7 of the implementation example and has the same effect as that of the positive control group; (ii) a (3) The other examples have slightly insufficient effects compared with the examples 4 or 7, but have significantly reduced serum Total Cholesterol (TC), serum Triglyceride (TG) and low-density lipoprotein cholesterol (HDL-C) and significantly increased serum high-density lipoprotein cholesterol (HDL-C) compared with the model control group, which indicates that the composition in the other examples has significant effects on reducing blood fat;
the perilla seed, the radish seed, the white mustard seed and the rhizoma acori graminei which are added in the formula and used for eliminating phlegm and dampness can better eliminate phlegm, dampness, turbidity and the like in blood, while the low-density lipoprotein cholesterol (HDL-C) which is a component which is bad for health needs to be phlegm, dampness, turbidity, phlegm elimination and dampness components in traditional Chinese medicine, and after the low-density lipoprotein cholesterol (HDL-C) is added, the low-density lipoprotein cholesterol (HDL-C) can be better reduced, so that the Total Cholesterol (TC) in serum is also reduced; the diglyceride oil component is added in the formula, so that the content of serum Triglyceride (TG) can be better reduced.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.
Claims (10)
1. A composition comprises the following traditional Chinese medicine components: radix salviae miltiorrhizae, angelica, caulis spatholobi, peach kernel, safflower, astragalus, cassia twig, earthworm, leech, rhizoma zedoariae, rhizoma ligustici wallichii, perillaseed, radish seed, semen brassicae, rhizoma acori graminei, poria cocos and arillus longan.
2. The composition according to claim 1, which comprises the following traditional Chinese medicine components in parts by weight: 10-30 parts of salvia miltiorrhiza, 5-15 parts of angelica sinensis, 10-25 parts of caulis spatholobi, 5-15 parts of peach kernel, 5-15 parts of safflower, 20-40 parts of astragalus membranaceus, 10-25 parts of cassia twig, 5-15 parts of earthworm, 5-15 parts of leech, 10-25 parts of curcuma zedoary, 10-25 parts of ligusticum wallichii, 5-15 parts of perillaseed, 5-15 parts of airy yam rhizome, 5-15 parts of airy kalimeris herb, 5-15 parts of semen brassicae, 5-15 parts of rhizoma acori graminei, 10-25 parts of poria cocos and 10-25 parts of arillus longan.
3. The composition of claim 1 or 2, further comprising a diglyceride.
4. The composition according to claim 3, characterized by comprising the following ingredients in parts by weight: 50-100 parts of diglyceride, 10-30 parts of salvia miltiorrhiza, 5-15 parts of angelica sinensis, 10-25 parts of caulis spatholobi, 5-15 parts of peach kernel, 5-15 parts of safflower, 20-40 parts of astragalus membranaceus, 10-25 parts of cassia twig, 5-15 parts of earthworm, 5-15 parts of leech, 10-25 parts of curcuma zedoary, 10-25 parts of ligusticum wallichii, 5-15 parts of perillaseed, 5-15 parts of airy raspberry, 5-15 parts of semen brassicae, 5-15 parts of rhizoma acori graminei, 10-25 parts of poria cocos and 10-25 parts of arillus longan.
5. The composition according to claim 4, comprising the following ingredients in parts by weight: 55-95 parts of diglyceride, 15-25 parts of salvia miltiorrhiza, 8-12 parts of angelica sinensis, 12-20 parts of caulis spatholobi, 8-12 parts of peach kernel, 8-12 parts of safflower, 25-35 parts of astragalus membranaceus, 12-20 parts of cassia twig, 8-12 parts of earthworm, 8-12 parts of leech, 12-20 parts of curcuma zedoary, 12-20 parts of ligusticum wallichii, 8-12 parts of perillaseed, 8-12 parts of airy raspberry, 8-12 parts of semen raphani, 8-12 parts of semen brassicae, 8-12 parts of rhizoma acori graminei, 12-20 parts of poria cocos and 12-20 parts of arillus longan.
6. A product whose main component is prepared from the composition according to any one of claims 1 to 5.
7. The product of claim 6, wherein the herbal ingredients are formulated as an extract, granules or powder, and the diglyceride is in the form of solid granules or powder.
8. The product of claim 6, further comprising a pharmaceutically acceptable excipient.
9. The preparation method of the product of any one of claims 6 to 8, wherein the traditional Chinese medicine components are prepared by extracting, filtering, purifying, concentrating into extract, granule or powder;
adding diglyceride solid granules or powder;
mixing the two solutions.
10. The method according to claim 9, wherein the diglyceride is a solid granule or a powder prepared by adding an emulsifier, a pH regulator, and an antioxidant to the diglyceride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210804111.2A CN115120692A (en) | 2022-07-09 | 2022-07-09 | Diglyceride composition for reducing blood fat and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210804111.2A CN115120692A (en) | 2022-07-09 | 2022-07-09 | Diglyceride composition for reducing blood fat and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115120692A true CN115120692A (en) | 2022-09-30 |
Family
ID=83381578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210804111.2A Pending CN115120692A (en) | 2022-07-09 | 2022-07-09 | Diglyceride composition for reducing blood fat and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115120692A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116672336A (en) * | 2023-08-03 | 2023-09-01 | 广东善百年特医食品有限公司 | Fat-reducing and weight-losing diglyceride composition and preparation method thereof |
| CN116746680A (en) * | 2023-06-17 | 2023-09-15 | 广东善百年特医食品有限公司 | Uric acid-reducing gout-relieving diglyceride composition and preparation method and application thereof |
-
2022
- 2022-07-09 CN CN202210804111.2A patent/CN115120692A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116746680A (en) * | 2023-06-17 | 2023-09-15 | 广东善百年特医食品有限公司 | Uric acid-reducing gout-relieving diglyceride composition and preparation method and application thereof |
| CN116672336A (en) * | 2023-08-03 | 2023-09-01 | 广东善百年特医食品有限公司 | Fat-reducing and weight-losing diglyceride composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU658614B2 (en) | Pharmaceutical compositions for the treatment of skin disorders | |
| CN115120692A (en) | Diglyceride composition for reducing blood fat and preparation method thereof | |
| WO2007006203A1 (en) | A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof | |
| US20080160075A1 (en) | Pharmaceutical Composition Made From Chinese Traditional Medicine And Method Of Producing Thereof | |
| CN105169118A (en) | Dendrobium officinale compound health buccal tablet and preparation method thereof | |
| CN101804103B (en) | Drug for treating leukopenia caused by concurrent chemoradiotherapy of malignant tumor and preparation method thereof | |
| CN101574476B (en) | Medicinal material composition used for lowering lipid and protecting liver auxiliarily | |
| CN103223104A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN105770579A (en) | Medicinal and edible homologous traditional Chinese medicine composition with liver-protecting effect | |
| CN101698085B (en) | Medicine composite for treating early liver fibrosis or early hepatocirrhosis decompensation, preparation method and application | |
| CN113368145A (en) | Traditional Chinese medicine composition and health-care food preparation for enhancing immunity | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN113318139A (en) | A Chinese medicinal composition used as both medicine and food for lowering blood sugar and reducing blood lipid | |
| CN107029124B (en) | Traditional Chinese medicine composition for treating primary hypertension and preparation method thereof | |
| CN101637563B (en) | Chinese medicinal composition for treating viral myocarditis and preparation process thereof | |
| CN104800600A (en) | Medicine for treating hypertension | |
| CN1839931B (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
| CN116920029B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN116115724B (en) | Traditional Chinese medicine composition, pharmaceutical preparation, preparation method and application thereof | |
| CN108159164A (en) | A kind of Chinese medicine composition of reducing blood lipid and preparation method thereof | |
| CN108721572B (en) | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |